|
81
|
Product specific BE guideline |
Amlodipine + Atorvastatin tablet_生體相等性試驗指導原則
|
2025-09-24 |
|
82
|
Product specific BE guideline |
Azacitidine Lyophilized Powder for Injection_生體相等性試驗指導原則
|
2025-09-24 |
|
83
|
Product specific BE guideline |
Deferasirox Tablet for suspension_生體相等性試驗指導原則
|
2025-09-24 |
|
84
|
Product specific BE guideline |
Dutasteride capsule_生體相等性試驗指導原則
|
2025-09-24 |
|
85
|
Product specific BE guideline |
Esomeprazole magnesium delayed release tablet_生體相等性試驗指導原則
|
2025-09-24 |
|
86
|
Quality |
病毒載體之基因治療製劑化學製造管制研發策略指導原則
|
2025-09-24 |
|
87
|
Pharm/tox |
藥品光安全性評估指導原則
|
2025-09-24 |
|
88
|
Product specific BE guideline |
Sildenafil Citrate Tablets_學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
89
|
Product specific BE guideline |
Dabigatran Etexilate Mesylate Hard Capsules_學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
90
|
Product specific BE guideline |
Agomelatine Tablet_生體相等性試驗指導原則
|
2025-09-24 |
